Powered by

Ensysce Biosciences, a California Based Biotech With a Mission to Solve the Opioid Crisis, Secures $60 Million Capital Commitment From Global Emerging Markets; Ensysce revolutionizing analgesia: tackling the biggest crises in US healthcare.

Dec 31, 2020 - Business Wire

Ensysce Biosciences Inc. is a clinical phase company launching two new classes of novel opioids designed to treat severe pain, and eliminate opioid misuse, abuse and overdose. Today Ensysce announced that it has signed an agreement with GEM Global Yield LLC SCS, (GEM) a Luxembourg-based private, alternative investment group.

Under the accord, GEM agrees to provide Ensysce with a share subscription facility of up to $60 million for a 36-month term following the public listing of the Company...